Staff

Matschl, Urte
Technician Virus ImmunologyPublications
Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich TJ, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Bokemeyer C, Sinn M, Lindig U, Hinke A, Hegewisch-Becker S, Stein A, Binder M (2025). Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy. Cancer Immunol Res. 13/2025; PubMed
Hernandez Torres LD, Rezende F, Peschke E, Will O, Hövener JB, Spiecker F, Özorhan Ü, Lampe J, Stölting I, Aherrahrou Z, Künne C, Kusche-Vihrog K, Matschl U, Hille S, Brandes RP, Schwaninger M, Müller OJ, Raasch W (2024). Incidence of microvascular dysfunction is increased in hyperlipidemic mice, reducing cerebral blood flow and impairing remote memory. Front Endocrinol (Lausanne). 15/2024; PubMed
Xie Y, Zhao F, Wang Y, Borowski S, Freitag N, Tirado-Gonzalez I, Hofsink N, Matschl U, Plösch T, Garcia MG, Blois SM (2024). Fetal growth restriction induced by maternal gal-3 deficiency is associated with altered gut-placenta axis. Cell Death Dis. 15/2024; PubMed
Gorgulho J, Loosen SH, Masood R, Giehren F, Pagani F, Buescher G, Kocheise L, Joerg V, Schmidt C, Schulze K, Roderburg C, Kinkel E, Fritzsche B, Wehmeyer S, Schmidt B, Kachel P, Rolling C, Götze J, Busch A, Sinn M, Pereira-Veiga T, Wikman H, Geffken M, Peine S, Matschl U, Altfeld M, Huber S, Lohse AW, Beier F, Brümmendorf TH, Bokemeyer C, Luedde T, von Felden J (2024). Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy. J Exp Clin Cancer Res. 43/2024; PubMed
Nickel L, Sünderhauf A, Rawish E, Stölting I, Derer S, Thorns C, Matschl U, Othman A, Sina C, Raasch W (2022). The AT1 Receptor Blocker Telmisartan Reduces Intestinal Mucus Thickness in Obese Mice. Front Pharmacol. 13/2022; PubMed
Beckmann L, Künstner A, Freschi ML, Huber G, Stölting I, Ibrahim SM, Hirose M, Freitag M, Langan EA, Matschl U, Galuska CE, Fuchs B, Knobloch JK, Busch H, Raasch W (2021). Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect. Pharmacol Res. 170/2021; PubMed
Huber G, Ogrodnik M, Wenzel J, Stölting I, Huber L, Will O, Peschke E, Matschl U, Hövener JB, Schwaninger M, Jurk D, Raasch W (2021). Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior. J Cereb Blood Flow Metab. 41/2021; PubMed
Langeneckert AE, Lunemann S, Martrus G, Salzberger W, Hess LU, Ziegler AE, Poch T, Ravichandran G, Matschl U, Bosse JB, Tiegs G, Fischer L, Koch M, Herkel J, Oldhafer KJ, Schramm C, Altfeld M (2019). CCL21-expression and accumulation of CCR7+ NK cells in livers of patients with primary sclerosing cholangitis. Eur J Immunol. 49/2019; PubMed
Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, Kasonta R, Zinser M, Stubbe H, Matschl U, Lohse A, Krähling V, Eickmann M, Becker S, , Thiébaut R, Altfeld M, Addo MM (2017). Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Rep. 20/2017; PubMed
Schommers P, Martrus G, Matschl U, Sirignano M, Lütgehetmann M, Richert L, Hope TJ, Fätkenheuer G, Altfeld M (2016). Changes in HIV-1 Capsid Stability Induced by Common Cytotoxic-T-Lymphocyte-Driven Viral Sequence Mutations. J Virol. 90/2016; PubMed
Franke C, Matschl U, Bruns M (2006). Enzymatic treatment of duck hepatitis B virus: topology of the surface proteins for virions and noninfectious subviral particles. Virology. 359/2007; PubMed
Guldner HH, Szostecki C, Schröder P, Matschl U, Jensen K, Lüders C, Will H, Sternsdorf T (1999). Splice variants of the nuclear dot-associated Sp100 protein contain homologies to HMG-1 and a human nuclear phosphoprotein-box motif. J Cell Sci. 112 ( Pt 5)/1999; PubMed